Pay in 4 interest-free payments of $7.45 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
in The New England Journal of Medicine
PlexusDx's compounded tirzepatide costs less than brand-name while offering the same active ingredient at flat monthly pricing starting at $289/month
Sales: $8.1 Billion Headcount: 4,500 Pharma Revenues: $8,102 (10%) Total Revenues : $8,385 (5%) Net Income: $2,804 (-3%) R&D Budget: $1,229 (15%) Top-Selling Drugs *All sales figures and related information presented in this report are based on data from the previous calendar year
Head-to-head trials showed patients lost more weight on tirzepatide than on semaglutide and by early 2025, prescription trends confirmed Novo was losing ground
At month 12, the mean change from baseline in the primary endpoint of HFMSE score in cohort 1 was -0.3 points in patients who received apitegromab plus nusinersen and -0.4 points in patients who received apitegromab alone
US$ 20.21
US$ 20.25
US$ 23.86
US$ 22.18
US$ 29.58
US$ 24.98
